APPLIED GENETIC TECHNOLOGIES CORP Net Change in Cash
APPLIED GENETIC TECHNOLOGIES CORP reported Net Change in Cash of -$9.20 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-21.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2022-11-21
- APPLIED GENETIC TECHNOLOGIES CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-09-30 was -$9.20M.
- APPLIED GENETIC TECHNOLOGIES CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-09-30 was -$14.54M.
- APPLIED GENETIC TECHNOLOGIES CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-09-30 was -$6.89M.
- APPLIED GENETIC TECHNOLOGIES CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2019-09-30 was -$10.43M.
- APPLIED GENETIC TECHNOLOGIES CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$58.69M, a 188.13% decline from fiscal 2021.
- APPLIED GENETIC TECHNOLOGIES CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $66.59M, a 466.23% increase from fiscal 2020.
- APPLIED GENETIC TECHNOLOGIES CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was $11.76M.
- APPLIED GENETIC TECHNOLOGIES CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was -$4.36M, a 1315.04% decline from fiscal 2018.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$9.20M 10-Q · filed 2022-11-21 | |||
| 2022-06-30 | -$58.69M 10-K · filed 2022-09-27 | |||
| 2022-03-31 | -$37.20M 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | -$32.28M 10-Q · filed 2022-02-14 | |||
| 2021-09-30 | -$14.54M 10-Q · filed 2022-11-21 | |||
| 2021-06-30 | $66.59M 10-K · filed 2022-09-27 | |||
| 2021-03-31 | $51.07M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$19.36M 10-Q · filed 2022-02-14 | |||
| 2020-09-30 | -$6.89M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $11.76M 10-K · filed 2021-09-23 | |||
| 2020-03-31 | $31.79M 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | -$8.63M 10-Q · filed 2021-02-11 | |||
| 2019-09-30 | -$10.43M 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | -$4.36M 10-K · filed 2020-09-18 | |||
| 2019-03-31 | -$9.49M 10-Q · filed 2020-05-13 | |||
| 2018-12-31 | -$7.09M 10-Q · filed 2020-02-05 | |||
| 2018-09-30 | -$4.59M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $359.00K 10-K · filed 2019-09-26 | |||
| 2018-03-31 | $16.93M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $39.64M 10-Q · filed 2019-02-07 | |||
| 2017-09-30 | $18.03M 10-Q · filed 2018-11-09 |